These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 11817288

  • 1. In vitro activity of moxifloxacin against local bacterial isolates.
    Ling ML, Tan PL.
    Ann Acad Med Singap; 2001 Nov; 30(6):607-10. PubMed ID: 11817288
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. In vitro activity of moxifloxacin against recent community-acquired respiratory tract pathogens isolated in France: a national survey.
    Decousser JW, Allouch PY, Courvalin P, Leclercq R, Study Group.
    Int J Antimicrob Agents; 2002 Sep; 20(3):186-95. PubMed ID: 12385697
    [Abstract] [Full Text] [Related]

  • 4. In vitro activity of moxifloxacin against common clinical bacterial isolates in Taiwan.
    Sheng WH, Wang JT, Chen YC, Chang SC, Luh KT.
    J Microbiol Immunol Infect; 2001 Sep; 34(3):178-84. PubMed ID: 11605808
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics.
    Nightingale CH.
    Pharmacotherapy; 2000 Mar; 20(3):245-56. PubMed ID: 10730681
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test.
    Madhusudhan KT, Counts C, Lody C, Carter O, Dodson S, Ojha N.
    Chemotherapy; 2003 Jul; 49(4):184-8. PubMed ID: 12886053
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparative in vitro activity of sitafloxacin against bacteria isolated from Thai patients with urinary tract infections and lower respiratory tract infections.
    Tiengrim S, Phiboonbanakit D, Thunyaharn S, Tantisiriwat W, Santiwatanakul S, Susaengrat W, Srisurat N, Malithong A, Srisangchan P, Thamlikitkul V.
    J Med Assoc Thai; 2012 Feb; 95 Suppl 2():S6-17. PubMed ID: 22574524
    [Abstract] [Full Text] [Related]

  • 11. Antimicrobial activity and accumulation of moxifloxacin in quinolone-susceptible bacteria.
    Piddock LJ, Jin YF.
    J Antimicrob Chemother; 1999 May; 43 Suppl B():39-42. PubMed ID: 10382874
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000-2001.
    Jones ME, Blosser-Middleton RS, Critchley IA, Karlowsky JA, Thornsberry C, Sahm DF.
    Clin Microbiol Infect; 2003 Jul; 9(7):590-9. PubMed ID: 12925097
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [National multicenter study of the in vitro activity of moxifloxacin against respiratory tract pathogens. Spanish Study Group on Moxifloxacin].
    Loza E, Morosini M, Negri MC, Almaraz F, Cantón R, Baquero F.
    Rev Esp Quimioter; 2000 Mar; 13(1):37-43. PubMed ID: 10855023
    [Abstract] [Full Text] [Related]

  • 16. Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens.
    Lopez H, Vilches V, Scarano S, Stepanik D, Smayevsky J, Lemme L, Cardeñosa O, Ambler J, Sucari A.
    Int J Antimicrob Agents; 2001 Oct; 18(4):379-82. PubMed ID: 11691572
    [Abstract] [Full Text] [Related]

  • 17. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study.
    Hoban DJ, Bouchillon SK, Johnson JL, Zhanel GG, Butler DL, Miller LA, Poupard JA, Gemifloxacin Surveillance Study Research Group.
    Diagn Microbiol Infect Dis; 2001 Oct; 40(1-2):51-7. PubMed ID: 11448564
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Benchmarking the in vitro activities of moxifloxacin and comparator agents against recent respiratory isolates from 377 medical centers throughout the United States.
    Jones ME, Staples AM, Critchley I, Thornsberry C, Heinze P, Engler HD, Sahm DF.
    Antimicrob Agents Chemother; 2000 Oct; 44(10):2645-52. PubMed ID: 10991838
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.